USA Micro Invasive Glaucoma Surgery (MIGS) Devices Market, By Product (MIGS Stents, MIGS Shunts and Others), Target (Trabecular Meshwork Suprachoroidal Space Subconjunctival Filtration and Reducing Aqueous Production), Surgery Type (Glaucoma in Conjunction with Cataract and Stand-Alone Glaucoma), End User (Hospital Outpatient Departments (HOPD), Ophthalmology Clinics, Ambulatory Surgery Centers (ASCS) and Others), Distribution Channel (Direct Tender and Retail Sales) – Industry Trends and Forecast to 2030.
USA Micro Invasive Glaucoma Surgery (MIGS) Devices Market Analysis and Size
Over the past few years, minimally invasive glaucoma surgery (MIGS) has become a viable treatment option for glaucoma. The only established method to stop glaucoma progression is to lower intraocular pressure (IOP). Historically, nonsurgical (such as topical medicines or laser therapy) and surgical methods have been used to accomplish this (trabeculectomy or glaucoma drainage devices). None of these approaches is perfect because surgical complications are frequent and drug compliance is the main problem. When treating patients with mild to moderate primary open-angle glaucoma, MIGS is frequently paired with cataract surgery due to its high safety profile, which enables it to be employed earlier than other types of glaucoma surgery (POAG).
Data Bridge Market Research analyses that the micro invasive glaucoma surgery (MIGS) devices market which is USD 537.32 million in 2022, is expected to reach USD 5519.27 million by 2030, at a CAGR of 33.8% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
USA Micro Invasive Glaucoma Surgery (MIGS) Devices Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (MIGS Stents, MIGS Shunts and Others), Target (Trabecular Meshwork Suprachoroidal Space Subconjunctival Filtration and Reducing Aqueous Production), Surgery Type (Glaucoma in Conjunction with Cataract and Stand-Alone Glaucoma), End User (Hospital Outpatient Departments (HOPD), Ophthalmology Clinics, Ambulatory Surgery Centers (ASCS) and Others), Distribution Channel (Direct Tender and Retail Sales)
|
|
Market Players Covered
|
Glaukos Corporation (U.S.), Ivantis Inc. (U.S), AbbVie Inc. (U.S.), Ellex (U.S.), Alcon (Switzerland), BVI (U.S.), Johnson and Johnson Surgical Vision Care Inc. (U.S.), Microsurgical technology (U.S.), Molteno Ophthalmic Ltd. (New Zealand), New world Medical Inc. (U.S.), Santen Pharmaceutical Co., Ltd. (Japan), Sight Scientific (U.S.), Bausch & Lomb Incorporated. (Canada), NeoMedix Healthcare India Pvt. Ltd. (U.S.) IOPtima (Israel)
|
|
Market Opportunities
|
|
Market Definition
Microinvasive glaucoma surgery is a form of glaucoma treatment (MIGS). It represents a significant advancement in the management of mild to moderate glaucoma. It provides an alternative to previously given drugs and does away with the risks associated with conventional surgery. These methods hope to avoid damaging the optic nerve by reducing intraocular pressure. Compared to standard surgery, these techniques are far safer and have a much shorter recovery time.
USA Micro Invasive Glaucoma Surgery (MIGS) Devices Market Dynamics
Drivers
- Increase in the occurrence of ophthalmic disorders
The growing ageing population and associated blindness are driving the market for micro invasive glaucoma surgery (MIGS) devices. Cataract and glaucoma are two of the most common age-related eye diseases in the elderly and major causes of blindness. Furthermore, rising demand for combined glaucoma and cataract treatment as a result of technological advancements in devices and growing patient awareness of minimally invasive surgeries is driving the growth of the micro invasive glaucoma surgery (MIGS) devices market.
- Rising incidence of glaucoma across the world
Major players in the ophthalmic treatment market are focusing on creating a stent for micro invasive glaucoma surgery (MIGS) for more effective treatments. As a result, demand for MIGS devices (micro invasive glaucoma surgery) is expected to increase.
- Introduction of technological advanced product
Glaucoma is a severe eye condition that, if left untreated, can cause vision loss. Since it is treatable with current medicine and there are numerous methods for limiting additional harm, it typically does not result in blindness. The way that glaucoma is treated has undergone a dramatic transformation as a result of greater scientific advancements. There has been a paradigm change in medicine with the introduction of micro-invasive glaucoma surgery since it can assist in the treatment of glaucoma at an early stage and eliminate the dependency on filtration operations such as trabeculectomy. Additionally, this eliminates the dangers related to these incisional surgeries. MIGS has made a number of improvements in the treatment of glaucoma.
Opportunities
- Government initiatives to increase awareness about the prevention of blindness
WHO estimates that at least 2.2 billion individuals worldwide have some form of vision impairment or blindness, at least 1 billion of them have a condition that might have been avoided. The government of many nations throughout the world has taken action to stop this. This fuels the market for micro invasive glaucoma surgery (MIGS) devices and increases the demand for cutting-edge therapies such as micro-invasive glaucoma surgery. Consequently, it is anticipated to operate as a market driver.
Restraints/Challenges
- Stringent regulations for MIGS devices
In the United States, any device manufacturer must comply with at least seven regulations, including Establishment Registration and Medical Device Listing, Premarket Notification 510(k), Premarket Approval (PMA) (only for class three devices), Investigational Device Exemption (IDE) for clinical studies, Quality System (QS) regulation, Labeling requirements, and Medical Device Reporting (MDR). These high-risk devices require a more stringent premarket application regulatory process to demonstrate valid evidence of safety and efficacy. Long timelines result in delayed access, which may limit the market for micro invasive glaucoma surgery (MIGS) devices.
This micro invasive glaucoma surgery (MIGS) devices market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the micro invasive glaucoma surgery (MIGS) devices market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Micro Invasive Glaucoma Surgery (MIGS) Devices Market
The COVID-19 pandemic is a global public health emergency that is projected to have a detrimental impact on the market for micro invasive glaucoma surgery (MIGS) devices. Glaucoma specialists prefer the trabeculectomy procedure for glaucoma surgery. Prior to the COVID-19 epidemic, the iStent inject, followed by XEN and Preserflo was the most frequently done MIGS device procedure in minimally invasive glaucoma surgery (MIGS). Although trabeculectomy is still the most common established glaucoma operation due to the reduced number of postoperative visits and medications, it is being performed with less frequency during the COVID-19 epidemic.
Recent Development
- In 2022, Glaukos announced the first patient enrollment in GLK=301's Phase II clinical trial for dry eye disease. This drug will help the company grow its business segment if the regulatory body approves it.
- In 2022, Alcon acquired Ivantis, the developer of the novel Hydrus Microstent, a minimally invasive glaucoma surgery (MIGS) device. This surgical device is intended to reduce eye pressure in patients with open-angle glaucoma. This acquisition will broaden the company's portfolio in eye surgery.
USA Micro Invasive Glaucoma Surgery (MIGS) Devices Market Scope
The micro invasive glaucoma surgery (MIGS) devices market is segmented on the basis of target, product, surgery type, distribution channel and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Target
- Trabecular Meshwork
- Suprachoroidal Space
- Subconjunctival Filtration
- Reducing Aqueous Production
- Others
Product
- MIGS Stents
- MIGS Shunts
- OTHER (TRABECTOME/MICRO-IMPLANTS/MICRO-CATHETERS)
Surgery Type
- Glaucoma in Conjunction with Cataract
- Stand-Alone Glaucoma
End User
- Hospital Outpatient Departments (HOPD)
- Ophthalmology Clinics
- Ambulatory Surgery Centers (ASCS)
- Others
Distribution Channel
- Direct Tender
- Retail Sales
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The micro invasive glaucoma surgery (MIGS) devices market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for micro invasive glaucoma surgery (MIGS) devices market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the micro invasive glaucoma surgery (MIGS) devices market. The data is available for historic period 2011-2021.
Competitive Landscape and Micro Invasive Glaucoma Surgery (MIGS) Devices Market Share Analysis
The micro invasive glaucoma surgery (MIGS) devices market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to micro invasive glaucoma surgery (MIGS) devices market.
Some of the major players operating in the micro invasive glaucoma surgery (MIGS) devices market are:
- Glaukos Corporation (U.S.)
- Ivantis Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Ellex (U.S.)
- Alcon (Switzerland)
- BVI (U.S.)
- Johnson and Johnson Surgical Vision Care Inc. (U.S.)
- Microsurgical technology (U.S.)
- Molteno Ophthalmic Ltd. (New Zealand)
- New world Medical Inc. (U.S.)
- Santen Pharmaceutical Co., Ltd. (Japan)
- Sight Scientific (U.S.)
- Bausch & Lomb Incorporated. (Canada)
- NeoMedix Healthcare India Pvt. Ltd. (U.S.)
- IOPtima (Israel)
SKU-